Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
{{output}}
Immunotherapy represented by anti-PD-(L)1 and anti-CTLA-4 inhibitors has revolutionized cancer treatment, but challenges related to resistance and toxicity still remain. Due to the advancement of immuno-oncology, an increasing number of novel immunoregulatory ... ...
